Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
NBNeurocrine Biosciences, Inc. logo

Neurocrine Biosciences, Inc. (NBIX)

NASDAQ Global Select · Currency in USD
$142.70 ▼ -0.59 (-0.41%)
At close: Oct 23, 4:00 PM ET. Market closed.
$141.50 ▼ -1.20 (-0.84%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$143.29
Open
$143.52
Day's Range
$140.90 – $143.61
52 Week Range
$122.14 – $186.12
Volume
1,033,366
Avg. Volume
1,277,068
Market Cap
$14.51B
Beta (5Y Monthly)
0.40
PE Ratio (TTM)
20.24
EPS (TTM)
$6.99
Earnings Date
Nov 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$204.18

Profile: Neurocrine Biosciences, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
2,500
CEO
Kyle W. Gano

Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia.

Earnings

Next report: Mon, Nov 2, 2026
EPS estimate $1.93 · Revenue est. $1.05B
DateEst.Actual
Jul 30, 2026$1.85$2.85Beat
May 5, 2026$1.22$1.91Beat
Feb 11, 2026$1.80$1.88Beat
Oct 28, 2025$1.58$2.04Beat
Jul 30, 2025$0.98$1.06Beat
May 5, 2025$0.54$0.08Miss

Analyst view

Consensus price target
$204.18 ▲ +43.1%
Range $165.00 – $230.00
Rating: Buy
Buy 86% · Hold 14% · Sell 0%

Get free alerts on NBIX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.